Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipolar mania. hubs.li/Q04BLx5Y0

Enlivex is cutting about 60% of staff to reduce costs and focus on mid-stage development of its knee osteoarthritis cell therapy, Allocetra. After another disappointing duravyu readout in wet AMD, EyePoint is reprioritizing and cutting about 53% of staff. hubs.li/Q04BLnPS0

METiS TechBio’s AiLNP platform uses machine learning models to develop lipid nanoparticles with potentially better tissue specificity that could enhance a drug’s therapeutic performance.

Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio. hubs.li/Q04BK06b0

The 3rd quarter offered positive signals for job seekers and talent acquisition teams. Explore BioSpace’s Biopharma Job Market Report Q3 2026 to get a closer look at hiring trends, workforce reductions and the evolving employment landscape. Download here: hubs.li/Q04BJZRh0

Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession. hubs.li/Q04BJWmX0

In this bonus episode, BioSpace Vice President of Marketing Chantal Dresner and Angela Gabriel, content manager, life sciences careers, discuss how the job market shaped up in Q3 and what Q4 might hold. hubs.li/Q04BKTLd0

The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus. hubs.li/Q04BJNRF0

EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to its potential in diabetic macular edema. hubs.li/Q04BJNfg0

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market. hubs.li/Q04Bz2-_0

AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone. hubs.li/Q04ByYw50

Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech. hubs.li/Q04ByxqF0

The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements. hubs.li/Q04By53p0

Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively. hubs.li/Q04By4RG0

Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light. hubs.li/Q04Bx_br0

In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill. hubs.li/Q04BxD4T0

High-quality cytokines for organoid growth, differentiation, and expansion hubs.li/Q04BxCQc0

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and many antibody-drug conjugates. hubs.li/Q04BxCGT0

While GLP-1 medicines are now synonymous with weight loss, one expert thinks amylin would have been the go-to target if biopharma had focused on the blockbuster indication 10 years ago. A new wave of therapies explores this potentially gentler mechanism. hubs.li/Q04BxB760

As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering partners to help navigate an expanding universe of molecular possibilities. hubs.li/Q04BxzBQ0